This clinical trial investigates the combined effects of transcranial direct current stimulation and Nordic walking exercise on motor symptoms in individuals with early-to-mid stage Parkinson's disease. By pairing non-invasive brain stimulation with whole-body aerobic exercise, the study aims to determine whether synergistic neuroplasticity mechanisms can produce greater motor improvements than either intervention alone. This Phase 2 randomized controlled trial seeks to establish proof-of-concept efficacy before larger confirmatory studies.
| Field | Value |
|-------|-------|
| Trial ID | NCT07381907 |
| Phase | Phase 2 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | tDCS + Nordic Walking combined therapy |
| Sponsor | [University Medical Center] |
| Start Date | 2025 |
| Completion Date | 2027 |
This clinical trial investigates the combined effects of transcranial direct current stimulation and Nordic walking exercise on motor symptoms in individuals with early-to-mid stage Parkinson's disease. By pairing non-invasive brain stimulation with whole-body aerobic exercise, the study aims to determine whether synergistic neuroplasticity mechanisms can produce greater motor improvements than either intervention alone. This Phase 2 randomized controlled trial seeks to establish proof-of-concept efficacy before larger confirmatory studies.
| Field | Value |
|-------|-------|
| Trial ID | NCT07381907 |
| Phase | Phase 2 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | tDCS + Nordic Walking combined therapy |
| Sponsor | [University Medical Center] |
| Start Date | 2025 |
| Completion Date | 2027 |
Parkinson's disease progressively impairs movement through several interconnected motor dysfunctions. Bradykinesia manifests as slowness that makes everyday activities increasingly difficult, while rigidity creates persistent muscle stiffness that limits range of motion. The characteristic resting tremor—involuntary shaking that subsides during intentional movement—often serves as the most visible early sign. Postural instability develops as the condition advances, causing balance difficulties that substantially raise fall risk and diminish independence. Pharmacological approaches like levodopa and dopamine agonists offer symptomatic relief but typically produce motor fluctuations and dyskinesias after prolonged use [@auto_10.31525_ct1-nct04237025].
Transcranial direct current stimulation delivers weak electrical currents through scalp electrodes to modulate how responsive brain tissue becomes. Anodal placement increases cortical excitability by depolarizing neuronal membranes, whereas cathodal stimulation produces the opposite effect. This modulation occurs through several interconnected mechanisms: shifts in neuronal membrane potential, alterations in NMDA receptor functioning, elevation of brain-derived neurotrophic factor, and subsequent enhancement of neuroplasticity. In Parkinson's disease, tDCS applied to the motor cortex and prefrontal regions has demonstrated the ability to improve UPDRS scores by approximately 10-25% while also mitigating levodopa-induced involuntary movements, all with minimal reported adverse effects.
Nordic walking employs purpose-built poles to simultaneously engage the upper body during walking, creating a whole-body conditioning activity. Beyond the lower extremities, this technique activates arm muscles, strengthens core stabilizers, and optimizes posture mechanics. The poles extend stride length and increase gait velocity while providing continuous proprioceptive feedback that sharpens balance. The cardiovascular demands exceed those of conventional walking, producing elevated heart rate responses and enhanced aerobic conditioning. Beyond physical adaptations, regular Nordic walking participation correlates with meaningful reductions in depression and anxiety symptoms [@auto_10.31525_ct1-nct04237025].
The therapeutic logic for pairing tDCS with Nordic walking emerges from their complementary mechanisms and non-pharmacological nature. First, the two interventions create synergistic neuroplastic effects: tDCS primes motor cortex excitability while exercise triggers BDNF-mediated plasticity changes that work through distinct yet reinforcing pathways. Second, the combined approach engages both central and peripheral mechanisms simultaneously—tDCS directly influences neural circuits while exercise addresses peripheral biomechanical and cardiovascular components. Third, for patients experiencing medication limitations or adverse effects, this non-pharmacological strategy offers a viable alternative for motor symptom management. Fourth, the dual intervention format enables comprehensive rehabilitation that concurrently targets motor function, balance, and gait performance [@j2024].
The trial employs a randomized, sham-controlled, double-blind design to establish rigorous efficacy evidence. Participants undergo 12 weeks of active intervention followed by 24 weeks of observation to assess durability. The study enrolls 120 individuals with early-to-mid stage Parkinson's disease, classified as Hoehn & Yahr stages 1-3, with equal allocation across four treatment arms.
| Arm | Intervention | Description |
|-----|--------------|-------------|
| 1 | Active tDCS + Nordic Walking | Real tDCS + supervised Nordic walking |
| 2 | Active tDCS + Standard Walking | Real tDCS + conventional walking |
| 3 | Sham tDCS + Nordic Walking | Inactive tDCS + supervised Nordic walking |
| 4 | Sham tDCS + Standard Walking | Inactive tDCs + conventional walking |
Eligibility requires confirmed Parkinson's disease diagnosis using UK Brain Bank criteria, disease stage within Hoehn & Yahr 1-3, and stable medication regimen for at least four weeks. Participants must demonstrate independent ambulation capability, with or without assistive devices, and cannot have previous tDCS experience. Cognitive screening via MMSE requires a minimum score of 24.
Several conditions preclude participation to ensure safety and validity. These include seizure history or epilepsy, metallic implants within the brain or skull, cardiac pacemakers or electronic devices, significant cardiovascular disease, orthopedic limitations that prevent walking, and concurrent enrollment in other rehabilitation trials.
Motor function serves as the primary efficacy endpoint, assessed through the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score. Gait performance is measured via the 6-Minute Walk Test, evaluating walking endurance capacity. Gait velocity is quantified using the 10-Meter Walk Test, capturing walking speed changes from baseline.
| Measure | Description | Timing |
|---------|-------------|--------|
| MDS-UPDRS Part III | Motor examination score | Baseline, Week 12, Week 36 |
| 6-Minute Walk Test | Gait endurance | Baseline, Week 12, Week 36 |
| 10-Meter Walk Test | Gait velocity | Baseline, Week 12, Week 36 |
Functional mobility, balance capabilities, and gait freezing patterns receive systematic evaluation through established clinical instruments. The Timed Up and Go test quantifies transition movements between seated and standing positions, while the Berg Balance Scale provides comprehensive postural stability assessment. Freezing of gait frequency and severity is captured through the dedicated FOG Questionnaire, with additional characterization through the Postural Instability and Gait Difficulty subscore.
Quality of life and non-motor symptom burden are incorporated as secondary endpoints, capturing treatment effects beyond raw motor performance. The PDQ-39 instrument assesses disease-specific quality of life across multiple domains, depressive symptoms are screened using the Beck Depression Inventory, and non-motor daily living experiences are documented through MDS-UPDRS Part I. Sleep quality receives evaluation via the Epworth Sleepiness Scale.
Corticospinal excitability changes are examined through motor evoked potentials and resting motor threshold measurements, providing objective neurophysiological correlates of treatment effects.
Comprehensive safety monitoring tracks adverse events throughout the intervention period, with specific attention to tDCS-related phenomena like skin irritation and headache, exercise-associated injuries, and falls frequency documented through daily diaries.
| Parameter | Value |
|-----------|-------|
| Current intensity | 2 mA |
| Duration | 20 minutes/session |
| Frequency | 5 sessions/week for 4 weeks (20 sessions) |
| Electrode size | 35 cm² |
| Placement | M1 (motor cortex) - anode, contralateral supraorbital - cathode |
Each session begins with pre-assessment including vital signs verification. Following baseline measurement, tDCS is applied for 20 minutes, followed by a 10-minute rest period to allow current dissipation. The exercise intervention component lasts 40 minutes, with post-session assessment documenting any immediate effects or concerns.
The progressive exercise program spans 12 weeks with escalating volume and intensity. Weeks 1-2 focus on technique acquisition with 30-minute sessions conducted three times weekly. Progressive walking loads are introduced during weeks 3-4 through 40-minute sessions. Interval training principles guide weeks 5-8 with 45-minute duration and increased cardiovascular demand. Weeks 9-12 emphasize endurance development through 50-minute sessions.
| Phase | Duration | Frequency | Focus |
|-------|----------|-----------|-------|
| Week 1-2 | 30 min | 3x/week | Technique training |
| Week 3-4 | 40 min | 3x/week | Progressive walking |
| Week 5-8 | 45 min | 3x/week | Interval training |
| Week 9-12 | 50 min | 3x/week | Endurance building |
Proper Nordic walking technique requires coordinated pole and body movements that maximize therapeutic benefit. The ergonomic handle design permits a diagonal grip that transfers force efficiently through the upper extremities. Poles are positioned at approximately 45-degree angles behind the body during the support phase, enabling proper propulsion mechanics. Arm swing follows an opposite pattern to leg movement, creating reciprocal coordination that engages trunk rotators. Core musculature remains active throughout to maintain upright posture and transfer force appropriately, while the stride deliberately extends during the push-off phase to lengthen gait.
The therapeutic synergy between tDCS and Nordic walking operates through several distinct but complementary mechanisms. Exercise-induced BDNF elevation amplifies the plasticity-promoting effects of tDCS, creating conditions more favorable for adaptive neural remodeling. Pre-activating the motor cortex through tDCS before exercise enhances motor learning and movement optimization during the subsequent physical training. The combined sensory and cortical stimulation may improve sensorimotor integration through gating mechanisms. Both interventions independently drive adaptive cortical reorganization, suggesting cumulative benefits when applied together.
The trial connects to multiple established Parkinson's disease mechanistic pathways. Substantia nigra degeneration represents the hallmark pathological feature underlying dopaminergic insufficiency, while vulnerable dopaminergic neurons demonstrate selective susceptibility to various insult types. Basal ganglia circuit dysfunction directly produces the motor manifestations this intervention targets.
Noradrenergic and cholinergic systems contribute substantially to non-motor symptoms and gait control in Parkinson's disease. Noradrenergic dysfunction appears in related conditions like progressive supranuclear palsy, while cholinergic degeneration contributes significantly to postural instability and falling.
Several parallel trials explore related questions. The tDCS for PD Gait trial examines stimulation effects specifically on walking performance, while trials targeting PSP motor function investigate transcranial stimulation in other parkinsonian syndromes. An ongoing intensity study evaluates whether dose optimization improves outcomes. Vibration therapy approaches offer alternative sensory modulation strategies.
Based on prior research, the active intervention group is anticipated to demonstrate meaningful motor improvements. MDS-UPDRS Part III scores should improve by 8-12 points relative to baseline, reflecting clinically meaningful motor function recovery. The 6-Minute Walk Test should show 15-25% improvement in covered distance, indicating enhanced gait endurance. Walking velocity measured by the 10-Meter Walk Test should increase by 10-15%, demonstrating improved gait speed.
Functional mobility should show 10-20% improvement in TUG performance time, while balance scales improve by 5-10 points. Quality of life measures should reflect 8-15% improvement specifically in the mobility domain.
Motor improvements are expected to persist through the 24-week follow-up period, with reduced fall frequency and maintained quality of life benefits extending beyond the active intervention phase.
| Milestone | Expected Date |
|-----------|---------------|
| First participant enrolled | Q1 2025 |
| Enrollment completion | Q4 2026 |
| Primary analysis | Q2 2027 |
| Results publication | Q4 2027 |
Several knowledge gaps remain to be addressed through future investigation. Stimulation parameter optimization requires systematic comparison of different intensities and electrode configurations to identify optimal dosing strategies. Biomarker development using neuroimaging techniques could enable prediction of individual treatment response, facilitating personalized medicine approaches. Protocol personalization based on disease stage and individual characteristics may enhance efficacy. Mechanistic studies should more thoroughly investigate BDNF changes and neuroplasticity markers to understand how combined interventions achieve their effects.
The following diagram shows the key molecular relationships involving tDCS + Nordic Walking for Parkinson's Disease Motor Symptoms (NCT07381907) discovered through SciDEX knowledge graph analysis: